A case of somatostatinoma: responses to food and SMS 201-995 administration.
Plasma somatostatin response to food and the administration of the long-acting somatostatin analogue SMS 201-995, as well as pituitary responses to insulin-induced hypoglycemia, growth hormone-releasing hormone (GHRH) and thyrotropin-releasing hormone (TRH), were assessed in a 60-year-old woman with biopsy-proven metastatic somatostatinoma. SMS 201-995 alone did not change plasma somatostatin-like immunoreactivity (SRIF), but levels of low-molecular-weight forms (SRIF-14 and SRIF-28) more than doubled in response to a standard meal. This postprandial response was not affected by pretreatment with SMS 201-995. Although a growth hormone response to insulin-induced hypoglycemia and supramaximal GHRH was absent, the patient's thyroid-stimulating hormone response to TRH was normal. These results suggest that somatostatin analogues may not influence tumor autonomy and that a SRIF response to food may contribute to early satiety in patients with somatostatinoma. In addition, the long-term use of somatostatin analogues to suppress hormone production by other peptide-secreting tumors may not have predictable results.
Davis
T M
TM
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
Bray
G
G
Domin
J
J
Bloom
S R
SR
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D005260:Female; D005502:Food; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D009496:Neurotensin / Q000097:blood; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010179:Pancreas / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010902:Pituitary Gland / Q000502:physiology; D013004:Somatostatin / Q000097:blood; D013005:Somatostatinoma / Q000188:drug therapy*
D009496:Neurotensin; D013004:Somatostatin; D015282:Octreotide